Clínica de las mamas

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Trial of Multi-epitope HER2 Peptide Vaccine in Patients with HER2-expressing DCIS

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to determine the safety, effcicacy and tolerability of H2NVAC in patients with HER2-expressing DCIS in order to  prevent future invasive breast cancer among patients who are diagnosed with DCIS.

2. A Study to Evaluate Feasibility of In Vivo Sensitivity Screen Using Direct Tumor Microinjection and FDG-PET in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

   Rochester, Minn.

   The purpose of this study is to assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions).

3. FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and trastuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving FASN inhibitor TVB-2640, paclitaxel, and trastuzumab may work better in treating patients with HER2 positive breast cancer.

4. A Study to Evaluate the Safety, Tolerability, Drug/Body Interactions, and Activity of Oradoxel for Patients with Advanced Malignancies

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the safety, tolerability, activity, and drug/body interactions of Oradoxel for the treatment of patients who have advanced malignancies.

5. Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

   Rochester, Minn., Mankato, Minn., La Crosse, Wis., Jacksonville, Fla., Albert Lea, Minn., Eau Claire, Wis.

   This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

6. A Study to Evaluate Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The primary purposes of this study are to evaluate the safety and tolerability of VE800 in combination with Nivolumab in terms of adverse event (AE) rates using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0), and to evaluate clinical activity as measured by objective response rate (ORR) of the study drug combination using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

7. A Study to Evaluate a Vaccine to Treat Patients with Invasive Metastatic Breast Cancer

   Rochester, Minn.

   To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP (MV-s-NAP) in patients with metastatic breast cancer; to determine the safety and toxicity of on-time and serial administration of MV-s-NAP in patients with metastic breast cancer. 

8. A Study to Evaluate Circulating Tumor DNA (ctDNA) and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer

   Rochester, Minn.

   The purpose of this study is to estimate the circulating tumor DNA (ctDNA)detection rate and mutational load in breast cancer patients with indications for regional nodal irradiation.

9. A Study of 3-D Digital Mammography to Screen Patients for Breast Cancer

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to evaluate digital tomosynthesis (3-D) mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

10. A Study of Low Dose Tamoxifen for Patients at High Risk for Breast Cancer

    Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to determine if counseling patients about low dose tamoxifen will influence the decision to take (or not take) preventive therapy among women at increased risk for breast cancer.

     

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Trial of Multi-epitope HER2 Peptide Vaccine in Patients with HER2-expressing DCIS

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to determine the safety, effcicacy and tolerability of H2NVAC in patients with HER2-expressing DCIS in order to  prevent future invasive breast cancer among patients who are diagnosed with DCIS.

2. A Study to Evaluate Feasibility of In Vivo Sensitivity Screen Using Direct Tumor Microinjection and FDG-PET in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

   Rochester, Minn.

   The purpose of this study is to assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions).

3. FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and trastuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving FASN inhibitor TVB-2640, paclitaxel, and trastuzumab may work better in treating patients with HER2 positive breast cancer.

4. A Study to Evaluate the Safety, Tolerability, Drug/Body Interactions, and Activity of Oradoxel for Patients with Advanced Malignancies

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the safety, tolerability, activity, and drug/body interactions of Oradoxel for the treatment of patients who have advanced malignancies.

5. Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

   Rochester, Minn., Mankato, Minn., La Crosse, Wis., Jacksonville, Fla., Albert Lea, Minn., Eau Claire, Wis.

   This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

6. A Study to Evaluate Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The primary purposes of this study are to evaluate the safety and tolerability of VE800 in combination with Nivolumab in terms of adverse event (AE) rates using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0), and to evaluate clinical activity as measured by objective response rate (ORR) of the study drug combination using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

7. A Study to Evaluate a Vaccine to Treat Patients with Invasive Metastatic Breast Cancer

   Rochester, Minn.

   To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP (MV-s-NAP) in patients with metastatic breast cancer; to determine the safety and toxicity of on-time and serial administration of MV-s-NAP in patients with metastic breast cancer. 

8. A Study to Evaluate Circulating Tumor DNA (ctDNA) and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer

   Rochester, Minn.

   The purpose of this study is to estimate the circulating tumor DNA (ctDNA)detection rate and mutational load in breast cancer patients with indications for regional nodal irradiation.

9. A Study of 3-D Digital Mammography to Screen Patients for Breast Cancer

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to evaluate digital tomosynthesis (3-D) mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.

10. A Study of Low Dose Tamoxifen for Patients at High Risk for Breast Cancer

    Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to determine if counseling patients about low dose tamoxifen will influence the decision to take (or not take) preventive therapy among women at increased risk for breast cancer.